0001437749-23-023162.txt : 20230811 0001437749-23-023162.hdr.sgml : 20230811 20230811080522 ACCESSION NUMBER: 0001437749-23-023162 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230811 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230811 DATE AS OF CHANGE: 20230811 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Perspective Therapeutics, Inc. CENTRAL INDEX KEY: 0000728387 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 411458152 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33407 FILM NUMBER: 231161597 BUSINESS ADDRESS: STREET 1: 350 HILLS STREET, STREET 2: SUITE 106 CITY: RICHLAND STATE: WA ZIP: 99354 BUSINESS PHONE: (509) 375-1202 MAIL ADDRESS: STREET 1: 350 HILLS STREET, STREET 2: SUITE 106 CITY: RICHLAND STATE: WA ZIP: 99354 FORMER COMPANY: FORMER CONFORMED NAME: Isoray, Inc. DATE OF NAME CHANGE: 20181231 FORMER COMPANY: FORMER CONFORMED NAME: IsoRay, Inc. DATE OF NAME CHANGE: 20050805 FORMER COMPANY: FORMER CONFORMED NAME: CENTURY PARK PICTURES CORP DATE OF NAME CHANGE: 19920703 8-K 1 isr20230809_8k.htm FORM 8-K isr20230512_8k.htm
false 0000728387 0000728387 2023-08-11 2023-08-11
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
FORM 8-K
 
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported): August 11, 2023
 
Perspective Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter)
 
Delaware
(State or Other Jurisdiction
of Incorporation)
001-33407
(Commission
File Number)
41-1458152
(IRS Employer
Identification No.)
 
350 Hills Street, Suite 106, Richland, Washington 99354
(Address of Principal Executive Offices) (Zip Code)
 
(509) 375-1202
(Registrant’s telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value
CATX
NYSE American
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
Item 2.02
 Results of Operations and Financial Condition.
 
On August 11, 2023, the Company issued a press release announcing its financial results for the second quarter of fiscal 2023 ended June 30, 2023, the text of which is attached hereto as Exhibit 99.1.
 
The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished pursuant to Item 2.02 and shall not be deemed “filed” for the
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
 
Item 9.01
Financial Statements and Exhibits.
 
 
(d)
Exhibits.
 
 
99.1
 Press release issued by Perspective Therapeutics, Inc., dated August 11, 2023.
 
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: August 11, 2023
 
Perspective Therapeutics, Inc.
 
 
By: /s/ Johan (Thijs) Spoor  
 
Johan (Thijs) Spoor
Chief Executive Officer
  
 
 
 
 
 EX-99.1 2 ex_559118.htm EXHIBIT 99.1 ex_559118.htm

Exhibit 99.1

 

logolg.jpg

 

Perspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business Highlights

 

 

●

Phase I/2a clinical trials initiated: VMT- α-NET for neuroendocrine tumors, and VMT01 for melanoma. Preliminary results from initial cohorts expected by end of 2023.

 

 

●

First patient dosed in Phase 1/2a dose escalation trial of VMT01 for treatment of MC1R-positive metastatic melanoma.

 

RICHLAND, WASHINGTON & CORALVILLE, IOWA – August 11, 2023 – Perspective, Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, reports second quarter financial results for the period ended June 30, 2023 and recent business highlights.

 

“We made substantial progress on our pipeline during Q2 2023 with the initiation of Phase 1/2a clinical trials for VMT-α-NET for neuroendocrine tumors and VMT01 for melanoma and we expect preliminary results from initial cohorts by end of the year,” said Thijs Spoor, Perspective Therapeutics’ CEO. “We are supplying both U.S. trials with drug product from our GMP manufacturing facility in Coralville, Iowa. We expect to bring additional CDMO manufacturing sites online in the coming months to enable broader coverage of sites across the U.S. Isotope will be supplied using Perspective’s proprietary VMT-α-GEN 212Pb benchtop generator.”

 

Andrew Bright, Perspective Therapeutics’ EVP of Brachytherapy noted, “Our brachytherapy business has emerged from the recent merger with an engaged and enthusiastic team that is focused on expanding the use of Cesium-131 brachytherapy. This quarter we have supplemented the team with talent in several key leadership areas. With a strong team in place, we’re focused on securing new business and re-gaining old business. We have a renewed focus on our strategic collaboration with GT Medical Technologies based on a shared belief that Cesium-131 is ideal for delivering radiotherapy to a key group of brain cancer patients. Our sales efforts will be bolstered by long-term Cesium-131 data in prostate cancer and additional peer reviewed data of Cesium-131 use in other cancers.”

 

Key Operation Highlights

 

 

●

The appointment of Heidi Henson as Audit Committee Chair of the Board of Directors. Ms. Henson brings over 25 years of executive leadership roles in the life sciences. In past executive leadership roles, Ms. Henson has served as the Chief Financial Officer of Pardes Biosciences, Imbria Pharmaceuticals, Respivant Sciences, Kura Oncology, Wellspring Biosciences, and Araxes Pharma.

 

 
 

 

 

●

The appointment of Andrew Bright as Executive Vice-President of Brachytherapy. Mr. Bright brings to Perspective over 30 years in leadership within the medical device industry, including over 20 years in brachytherapy. Mr. Bright was part of the commercial enterprise responsible for initial widespread adoption and growth of brachytherapy in the 1990’s and was involved in the development and introduction of some of the most successful and clinically relevant products in the industry.
 

●

The appointment of Shane Cobb as Executive Vice President of Operations. Mr. Cobb brings a wealth of operational nuclear pharmacy industry experience to Perspective. He worked for 35 years in roles of increasing responsibility at Roche, Medi+Physics, Amersham, Nycomed Amersham, GE Healthcare, and RLS. Adding to his extensive knowledge of the space, during his time at GE Healthcare, he led multiple global scale projects including bringing a new Mo-99 generator offering to the US, spearheading safety improvement initiatives, developing production workflow systems for 31 cleanrooms to meet USP 797 compliance, and leading the first nuclear pharmacies in the US to receive Joint Commission accreditation for quality standards.
 

●

Launch of Australian subsidiary to accelerate the commencement of early-stage clinical R&D work. The launch of this entity is intended to accelerate Perspective’s translational pipeline products from preclinical into early phase proof of concept human clinical trials.

 

VMT01 Clinical Highlights

 

 

●

Initiated clinical trial sites and commenced the enrollment period for 212Pb labeled therapeutic product candidate VMT01 for the treatment of melanoma. VMT01 is entering therapeutic trials at leading U.S. institutions.
 

●

Multiple patients screened and first patient dosed in Phase 1/2a Dose Escalation Trial for VMT01 in the treatment of metastatic melanoma expressing MC1R. Preliminary data readout from dose escalation study is expected by the end of 2023.
 

●

First in human imaging data from VMT01 were presented at the 2023 Annual Society for Nuclear Medicine and Molecular Imaging (SNMMI) by Geoffrey Johnson, MD, PhD, the Chair of Nuclear Medicine at Mayo Clinic. Dr. Johnson noted that both the SPECT and PET imaging versions of VMT01 showed favorable uptake in melanoma tumors in a subset of patients, confirming VMT01/VMT02 as selection tools for patients to receive targeted alpha therapy with 212Pb-VMT01.
 

●

Preclinical combination data with checkpoint inhibitors were presented at the 2023 International Symposium on Radiopharmaceutical Sciences (iSRS). Data displayed synergy between targeted alpha therapy with 212Pb and immune checkpoint inhibitors.

 

VMT-α-NET Recent Milestones

 

 

●

Continued administrations of multiple cycles of administering VMT-α-NET in 10 patients in an investigator-initiated trial at Fortis Memorial Research Institute. We expect to disclose preliminary results in Q3 2023.
 

●

Initiated clinical trial sites and commenced the enrollment period for 212Pb labeled therapeutic product candidate VMT-α-NET. VMT-α-NET for neuroendocrine cancers is entering therapeutic trials at leading US institutions.
 

●

Continued recruitment in University of Iowa imaging and dosimetry study with 203Pb VMT-α-NET.

 

 
 

 

Brachytherapy Recent Highlights

 

 

●

A favorable comparison between Cesium-131 brachytherapy and Stereotactic Body Radiation Therapy, along with long-term Cesium-131 data, was presented at the American Brachytherapy Society annual meeting. The data showed that Cesium-131 brachytherapy offers prostate cancer patients the prospect of disease-free survival of 96% measured at ten years after treatment.
 

●

Bander et al. published a retrospective review of brain tumor treatment using surgery and Cesium-131 brachytherapy in the Journal of Neuro-Oncology. The study highlighted the superior local tumor control and lower complication rates of Cesium-131 compared to Iodine-125 data. (Bander, ED, et al., Safety and efficacy of Cesium-131 brachytherapy for brain tumors. Journal of Neurosurgery 163(2): 355-365. (2023)).
 

●

Established an initiative with GT Medical Technologies, Inc. (GT Medical) to broaden access to their GammaTile® Therapy product, a unique delivery method for placing Cesium-131 during the last five minutes of brain tumor resection surgery.
 

●

The Centers for Medicare & Medicaid Services announced in July 2023 its proposed Medicare Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems payment rates for 2024. Under these rates, Perspective’s stranded pre-loaded Cesium-131 seeds would see an increase in reimbursement per seed. The final rule will be issued in November 2023.

 

Manufacturing and Supply Milestones

 

 

●

Updated all regulatory, operational, and related compliance activities to ensure all FDA related labeling, documentation, packaging, and customer facing materials reflects Perspective Therapeutics, with no disruption or inconvenience to our customers.
 

●

Multiple clinical GMP products have now been manufactured and shipped to clinical sites from Perspective’s GMP facility in Coralville.
 

●

Substantial progress towards transfer of manufacturing to multiple third party contract development and manufacturing organization sites well underway.
 

●

212Pb generators manufactured and shipped worldwide have shown robustness of supply.
 

●

Additional supplies of Th-228 feedstock have been identified to enable plentiful quantities of 212Pb to be purified as development of Perspective’s pipeline of products progresses towards commercialization.
 

●

Continued to increase its manufacturing in support of GT Medical’s objective of delivering GammaTile® Therapy to more patients with difficult to treat brain cancers.

 

Second Quarter and Half Year 2023 Financial Summary

 

Revenue - Revenue for the three months ended June 30, 2023 was $2.1 million, as compared to $2.5 million in the same period in 2022, a decline of 17%. The year-over-year decline in revenue was primarily a result of the loss of a large brachytherapy customer partially offset by grant revenue related to our alpha-particle therapy operations.

 

Gross Profit - Gross profit was $248,000 for the three months ended June 30, 2023, as compared to $926,000 for the same period in 2022, a decline of 73%. The year over year decline was primarily a result of the decrease in sales due to the loss of a large brachytherapy customer, higher brachytherapy production costs, and a $298,000 write-off of Blu Build inventory as the Company discontinued selling its loader, and were partially offset by grant revenue from our alpha-particle therapy business.

 

 
 

 

Research and development (R&D) expenses - R&D for the three months ended June 30, 2023 and 2022 comparison was an increase in costs of $4.9 million related to the development of the Company’s alpha-particle therapy drug products gained through the merger with Viewpoint, partially offset by a decrease in the Company’s legacy research and development expenses.

 

Management believes that research and development expenses will increase as we continue to invest in the development of new drugs and products.

 

Net loss - For the second quarter of 2023, the Company reported a net loss of $11.1 million, compared to a net loss of $2.1 million in the same period in 2022.

 

For the first half of fiscal 2023 ended June 30, 2023, revenue decreased 23% to $4.2 million versus $5.4 million in the prior year comparable period. Prostate brachytherapy represented 42% of total revenue for the first six months of fiscal 2023 compared to 73% for the first six months of fiscal 2022. Total operating expenses for the first six months of fiscal 2023 increased 299% to $23.3 million, versus $5.8 million in the prior year comparable period. The net loss for the first six months of fiscal 2023 was $11.5 million, or ($0.05) per basic and diluted share, compared to a net loss of $3.4 million, or ($0.02) per basic and diluted share, in the prior year comparable period. Basic and diluted per share results are based on weighted average shares outstanding of approximately 254 million for the six months ended June 30, 2023, versus 142 million in the comparable prior year period.

 

Cash and cash equivalents - As of June 30, 2023, cash, cash equivalents, and restricted cash was $28.5 million as compared to cash, cash equivalents, restricted cash, and short-term investments totaled $43.9 million as of December 31, 2022.

 

 

About Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc., is a medical technology and radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body. The Company is the sole producer of Cesium-131 brachytherapy seeds and has a proprietary technology that utilizes the isotope Lead-212 to deliver powerful alpha radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This “theranostic” approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.

 

The Company’s melanoma (VMT-01) and neuroendocrine tumor (VMT-α-NET) programs are entering Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary lead-212 generator to secure isotope supply for clinical trial and commercial operations.

 

For more information, please visit the Company’s website at www.perspectivetherapeutics.com.

 

 
 

 

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company's clinical development plans and the expected timing thereof; the expected timing for availability and release of data; the Company’s timing and expectations regarding regulatory communications, submissions and approvals; expectations regarding the potential market opportunities for the Company’s product candidates; the potential functionality, capabilities, and benefits of the Company’s product candidates; the potential size of the commercial market for the Company’s product candidates; the Company’s expectations, beliefs, intentions, and strategies regarding the future; the Company’s expectations regarding the addition of manufacturing sites; the Company’s expectations regarding supplying isotope using its proprietary benchtop generator; the Company’s expectations regarding potential competitors; the Company’s plans for bolstering sales efforts; the Company’s expectations regarding changes in reimbursement amounts for its products; the Company’s ability to transfer its manufacturing to third parties; and other statements that are not historical fact.

 

The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company’s actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation, the potential that regulatory authorities may not grant or may delay approval for the Company’s product candidates; uncertainties and delays relating to the design, enrollment, completion, and results of clinical trials; unanticipated costs and expenses; early clinical trials may not be indicative of the results in later clinical trials; clinical trial results may not support regulatory approval or further development in a specified indication or at all; actions or advice of regulatory authorities may affect the design, initiation, timing, continuation and/or progress of clinical trials or result in the need for additional clinical trials; the Company’s ability to obtain and maintain regulatory approval for the Company’s product candidates; delays, interruptions or failures in the manufacture and supply of the Company’s product candidates; the size and growth potential of the markets for the Company’s product candidates, and the Company’s ability to service those markets; the Company’s cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated; the Company’s expectations, projections and estimates regarding expenses, future revenue, capital requirements, and the availability of and the need for additional financing; the Company’s ability to obtain additional funding to support its clinical development programs; the availability or potential availability of alternative products or treatments for conditions targeted by the Company that could affect the availability or commercial potential of its product candidates; the ability of the Company to manage growth and successfully integrate its businesses; whether the Company can maintain its key employees; whether there is sufficient training and use of the Company’s products and product candidates; the market acceptance and recognition of the Company’s products and product candidates; the Company’s ability to maintain and enforce its intellectual property rights; whether the Company can maintain its therapeutic isotope supply agreement with the Department of Energy; whether the Company will continue to comply with the procedures and regulatory requirements mandated by the FDA for additional trials, Phase 1 and 2 approvals, Fast Track approvals, and 510(k) approval and reimbursement codes; and any changes in applicable laws and regulations. Other factors that may cause the Company’s actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading “Risk Factors” in the Company’s most recent Transition Report on Form 10-KT and the Company’s most recent Quarterly Report on Form 10-Q, each filed with the Securities and Exchange Commission (the “SEC”), in the Company’s other filings with the SEC, and in the Company’s future reports to be filed with the SEC and available at www.sec.gov.

 

Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information whether as a result of new information, future events or otherwise, except as required under applicable law.

 

 

Investor Relations Contact:

LifeSci Advisors

Chuck Padala

E: chuck@lifesciadvisors.com

 

 
 

 

Perspective Therapeutics, Inc. and Subsidiaries 

Condensed Consolidated Balance Sheets  (Unaudited)

(In thousands, except shares) 

 

   

June 30,

   

December 31,

 
   

2023

    

2022

  

ASSETS

               

Current assets:

                

Cash and cash equivalents

   $ 28,319     $ 20,993  

Short-term investments

     -       22,764  

Accounts receivable, net

     1,113       1,363  

Inventory

     1,094       1,409  

Note receivable

     -       6,109  

Prepaid expenses and other current assets

     1,428       577  
                 

Total current assets

     31,954       53,215  
                 

Property and equipment, net

     7,043       1,684  

Right of use asset, net

     805       378  

Restricted cash

     182       182  

Inventory, non-current

     2,269       2,396  

Intangible assets

     50,000       -  

Goodwill

     27,319       -  

Other assets, net

     573       236  
                 

Total assets

   $ 120,145     $ 58,091  
                 

LIABILITIES AND STOCKHOLDERS' EQUITY

               
                 

Current liabilities:

                

Accounts payable and accrued expenses

   $ 4,906     $ 1,541  

Lease liability

     262       276  

Accrued protocol expense

     387       233  

Accrued radioactive waste disposal

     20       129  

Accrued payroll and related taxes

     2,259       212  

Accrued vacation

     684       285  

Other notes payable, current

     71       -  
                 

Total current liabilities

     8,589       2,676  

Non-current liabilities:

                

Lease liability, non-current

     543       116  

Note payable

     1,701       -  

Asset retirement obligation

     659       657  
                 

Total liabilities

     11,492       3,449  

Commitments and contingencies

                
                 

Stockholders' equity:

                

Preferred stock, $.001 par value; 7,000,000 shares authorized: Series B: 5,000,000 shares allocated; no shares issued and outstanding

     -       -  

Common stock, $.001 par value; 750,000,000 shares authorized; 280,479,421 and 142,112,766 shares issued and outstanding

     280       142  

Additional paid-in capital

     225,782       160,432  

Accumulated deficit

     (117,409

)

     (105,932

)
                 

Total stockholders' equity

     108,653       54,642  
                 

Total liabilities and stockholders' equity

   $ 120,145     $ 58,091  

 

 
 

 

Perspective Therapeutics, Inc. and Subsidiaries 

Condensed Consolidated Statements of Operations (Unaudited) 

(Dollars and shares in thousands, except for per-share amounts) 

 

   

Three months ended

    

Six months ended

  
   

June 30,

   

June 30,

 
   

2023

    

2022

    

2023

    

2022

  
                                 

Sales, net

   $ 1,500     $ 2,505     $ 3,330     $ 5,415  

Grant revenue

     588       -       821       -  

Total revenue

     2,088       2,505       4,151       5,415  

Cost of sales

     1,840       1,579       3,416       3,048  

Gross profit

     248       926       735       2,367  
                                 

Operating expenses:

                                

Research and development

     5,653       796       9,510       1,345  

Sales and marketing

     911       654       1,723       1,341  

General and administrative

     5,073       1,582       12,096       3,163  

Change in estimate of asset retirement obligation

     (15

)

     -       (15

)

     -  

Loss on disposal of property and equipment

     -       -       22       -  

Total operating expenses

     11,622       3,032       23,336       5,849  
                                 

Operating loss

     (11,374

)

     (2,106

)

     (22,601

)

     (3,482

)
                                 

Non-operating income (expense):

                                

Interest income

     294       28       668       57  

Interest expense

     (28

)

     -       (46

)

     -  

Other income

     2               2       -  

Non-operating income, net

     268       28       624       57  
                                 

Net loss before deferred income tax benefit

     (11,106

)

     (2,078

)

     (21,977

)

     (3,425

)
                                 

Deferred income tax benefit

     -       -       10,500       -  
                                 

Net loss

   $ (11,106

)

   $ (2,078

)

   $ (11,477

)

   $ (3,425

)
                                 

Basic and diluted loss per share

   $ (0.04

)

   $ (0.01

)

   $ (0.05

)

   $ (0.02

)
                                 

Weighted average shares used in computing net loss per share:

                                

Basic and diluted

     279,988       142,040       254,432       142,040  

 

 
 EX-101.SCH 3 isr-20230811.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 isr-20230811_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 isr-20230811_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, Address Line Two Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Emerging Growth Company Amendment Flag Entity, Central Index Key EX-101.PRE 6 isr-20230811_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 logolg.jpg begin 644 logolg.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document And Entity Information
Aug. 11, 2023
Document Information [Line Items]  
Entity, Registrant Name Perspective Therapeutics, Inc.
Document, Type 8-K
Document, Period End Date Aug. 11, 2023
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-33407
Entity, Tax Identification Number 41-1458152
Entity, Address, Address Line One 350 Hills Street
Entity, Address, Address Line Two Suite 106
Entity, Address, City or Town Richland
Entity, Address, State or Province WA
Entity, Address, Postal Zip Code 99354
City Area Code 509
Local Phone Number 375-1202
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol CATX
Security Exchange Name NYSEAMER
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0000728387
XML 9 isr20230809_8k_htm.xml IDEA: XBRL DOCUMENT 0000728387 2023-08-11 2023-08-11 false 0000728387 8-K 2023-08-11 Perspective Therapeutics, Inc. DE 001-33407 41-1458152 350 Hills Street Suite 106 Richland WA 99354 509 375-1202 false false false false Common Stock CATX NYSEAMER false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( *I "U<'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "J0 M7#<^3J.X K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2L0P$(=?17)O)VE1)'1S43PI""XHWD(RNQML_I",M/OVMG6WB^@#>,S,+]]\ M ].9)$W,^)QCPDP.R]7H^U"D21MV($H2H)@#>EWJ*1&FYBYFKVEZYCTD;3[T M'J'A_ 8\DK::-,S *JU$ICIKI,FH*>83WIH5GSYSO\"L >S18Z "HA; U#PQ M'<>^@PM@AA%F7[X+:%?B4OT3NW2 G9)C<6MJ&(9Z:)?/ MC<^"JH-?=Z&^ %!+ P04 " "J0 M7F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M *I "U=[ <%W6P0 $(1 8 >&PO=V]R:W-H965T&UL MI9AM;^HV%,>_BI5)TR:5)DZ@T Z0**6[Z-[VHL+6/6@O3&+ :A)GME/*M]]Q M@(3IAA.F]47S9/_S\_'Q_\3TMU*]Z0WGAGPD<:H'SL:8[,YU=;CA"=/7,N,I M/%E)E3 #EVKMZDQQ%A6=DMCU/>_&39A(G6&_N#=3P[[,32Q2/E-$YTG"U.Z> MQW([<*ASO/$BUAMC;[C#?L;6?,[-+]E,P95;JD0BX:D6,B6*KP;.B-[=^QW; MH6CQJ^!;?7).[%"64K[9BVDT<#Q+Q&,>&BO!X/#.QSR.K1)P_'T0=FZ7ZV(6I]U\!+;%,W/ C> M[P7],X*C?'U-*+TBON<'_^[N EL)Z)> ?J$7- &>4)$_OT K,C4\T7_5(>XE MV_62-M'O=,9"/G @DS57[]P9?O\=O?%^0H"#$CC U(?[(%Z1%[X6VB@&Z,\L MX768N-",*YWQ(FO)8L,5RWAN1*BO(!3A-4+:+DG;Z N.H;TBBUU6"XCW[[4^ M(Q2=DJ)S(04,6$B;A1&!7*X%PJ7*W&M*OIN2[>:BN82 2Y5)563?%9D;P"-2 MD;',4Z-V<(QJ<7'UAPF"V"T1NQ!YM!4';ZR) O1*H M=Q'0@GV0:003*U8BW"_;\WBX9)NV:+O3HQT?X;LM^6XOXAM%$2Q^79Z0PE.^ MIK43B4L&'8]\$G&L(3,4.#%"2;W*F+W_P;G8REIOQC7GN8#$I=X-1GA2.NA_ M(QS;Z@'+8B&W]94#UWL1X29F:83!566#HB;_+5RY:&=*OHLTK)WG!M'7$<96 M50AZ68DHV692&Q:3/T1VUDH:)&]O@TX;@ZN* L5=O9C$$7SAG4?!!3K>+092 MU06*N_D7&4),9AN98L;6(!)T.RT*U0 CJJH!Q0W[50EC> J!29(\/;B:KJ7" MA58LUAQ#JMR?XLX]E[$(A1'IFCQ!?BO!XEH>7*61IS)_BEOU3/%6".'AL,"* MS[8%3R.NR-?5ZLS\X7J-9)7M4]RDOR&;:IT#62,@+ML$Z%>&[^/FO! &2KA< M$>K_L/R1S'F80[[M:K]O<26;GU!NYT:&;QA:Y?0^[LP+Q2*;8O-=LI2U"=8@ M,!XM?L-(3G8#N ,?HT(F'^&&I6M^]N.Z0>CY]_ED]#1YP:@J0_0[%&1\(\Q6]>BX *-*)6C^[@9'\,T M!AH%WCZ%E?=!/O/Z .%:'OQU_5[0J_UF=4]VQ/;7A2=FYT63F*] S;ON@KC: M;]CW%T9FQ29Y*0ULN8O3#6=@#+8!/%]):8X7=M]=_FPR_ =02P,$% @ MJD +5Y^@&_"Q @ X@P T !X;"]S='EL97,N>&ULW5=M:]LP$/XK0C]@ M;F)JXI$8MD!AL(U"\V%?E5AV!'KQ9+ES^NNGLVPG:75EW8>QS:')W3VZNT=W M)YFN6W>2_.'(N2.]DKK=T*-SS?LD:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP M4C)9WMQDB6)"TV*M.W6G7$L.IM-N0V]H4JPKH\^6E :#7\H4)X],;NB62;&W M8EC+E)"G8%Z"X6"DL<1Y*GQ#%V!IGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM M5X64,\$E#89BW3#GN-5W7AD6#\87$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLY MS8).IF(M>05TK*B/\.M,DP#HG%%>* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5B M'_2^FO-CT1=X=-8T\O1!BEHK'O;^RPF+-9O\R-%8\>2SP:0)P M:?EA6;/CO9NFJ:]PSLM_D/.?K7/--;=,7I+VH_\W5_DMC)/Q]%PZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X M3O,\3;,,J^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3 MB.T4KS4@\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0ERHY_U=3 M_ 102P,$% @ JD +5Y>*NQS $P( L !?3T\$MP> M:4#M.*2VBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5; M&GC3Y?YVX$G1H2)8%II%R=.B':5_'36TGH MX-R#8._AE8P=S8\?=_<#4$L#!!0 ( *I "U&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q= M6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\ MI%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*'3^ 5!+ P04 " "J0 M799!YDAD! #/ P M$P %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M= M< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4' M3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!- MFI6.5Z*U .EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXP MC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T, M:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0 ( M *I "U<'04UB@0 +$ 0 " 0 !D;V-0&UL4$L! A0#% @ JD +5PW/DZCN *P( !$ M ( !KP &1O8U!R;W!S+V-O&UL4$L! A0#% @ JD +5YEP'!=UL$ !"$0 & @($-" M>&PO=V]R:W-H965T&UL4$L! A0#% @ JD +5Y^@&_"Q M @ X@P T ( !G@P 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% @ JD +5R0>FZ*M M^ $ !H ( !T!$ 'AL+U]R96QS+W=O9(9 0 SP, !, ( ! MM1( %M#;VYT96YT7U1Y<&5S72YX;6Q02P4& D "0 ^ @ _Q, end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.isr.com/20230811/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports isr20230809_8k.htm ex_559118.htm isr-20230811.xsd isr-20230811_def.xml isr-20230811_lab.xml isr-20230811_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "isr20230809_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "definitionLink": { "local": [ "isr-20230811_def.xml" ] }, "inline": { "local": [ "isr20230809_8k.htm" ] }, "labelLink": { "local": [ "isr-20230811_lab.xml" ] }, "presentationLink": { "local": [ "isr-20230811_pre.xml" ] }, "schema": { "local": [ "isr-20230811.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] } }, "elementCount": 27, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "isr", "nsuri": "http://www.isr.com/20230811", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "isr20230809_8k.htm", "contextRef": "d20238K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.isr.com/20230811/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "isr20230809_8k.htm", "contextRef": "d20238K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.isr.com/20230811/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.isr.com/20230811/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.isr.com/20230811/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document, Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.isr.com/20230811/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document, Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.isr.com/20230811/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity, Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.isr.com/20230811/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity, Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.isr.com/20230811/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity, Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.isr.com/20230811/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity, Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.isr.com/20230811/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity, Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.isr.com/20230811/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity, Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.isr.com/20230811/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.isr.com/20230811/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity, Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.isr.com/20230811/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity, File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.isr.com/20230811/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity, Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.isr.com/20230811/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity, Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.isr.com/20230811/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity, Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.isr.com/20230811/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.isr.com/20230811/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.isr.com/20230811/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.isr.com/20230811/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.isr.com/20230811/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.isr.com/20230811/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.isr.com/20230811/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.isr.com/20230811/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.isr.com/20230811/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.isr.com/20230811/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001437749-23-023162-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-23-023162-xbrl.zip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